MANNKIND CORP

MNKDSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 899460

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$199.0M	$99.8M	$75.4M	$65.1M	$65.1M
Cost of Goods and Services Sold	$20.9M	$16.0M	$16.8M	$15.1M	$15.1M
Selling, General and Administrative Expense	$94.3M	$91.5M	—	—	$59.0M
Operating Expenses	$62.8M	$57.5M	$38.9M	$24.6M	—
Operating Income (Loss)	$8.7M	-$64.1M	-$47.0M	-$47.9M	-$47.9M
Interest Expense	—	—	$15.2M	$1.4M	—
Nonoperating Income (Expense)	-$19.1M	-$23.3M	-$33.9M	-$9.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$393.8M	$475.2M	$295.3M	$321.2M	$108.6M
Assets, Current	$268.3M	$373.4M	$234.9M	$219.5M	$79.5M
Cash and Cash Equivalents, at Carrying Value	$46.3M	$238.5M	$69.8M	$124.2M	$67.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$11.8M	$14.9M	$16.8M	$4.7M	$4.2M
Inventory, Net	$27.9M	$28.5M	$21.8M	$7.2M	$5.0M
Liabilities	$472.7M	$721.4M	$545.8M	$530.5M	$289.0M
Liabilities, Current	$81.8M	$104.1M	$67.3M	$48.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$34.1M	-$80.7M	-$61.7M	-$28.1M	-$28.1M
Net Cash Provided by (Used in) Investing Activities	-$2.0M	$4.9M	-$151.5M	$15.2M	$15.2M
Net Cash Provided by (Used in) Financing Activities	$136.6M	$21.4M	$270.3M	$49.9M	$49.9M
Payments to Acquire Property, Plant, and Equipment	$42.4M	$7.6M	$11.5M	$801.0K	$801.0K
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)